Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
High risk of MS in Iranian immigrants in Gothenburg, Sweden.
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis.
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial.
Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
Response to "Glucocorticoids for treating Takotsubo syndrome?" and "Atypical global Takotsubo syndrome in a patient with acute disseminated encephalomyelitis".
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
The mammalian Na+/H+ exchanger gene family--initial structure/function studies.
Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis.
Mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis.
Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
Correlation between demyelinating lesions and executive function decline in a sample of Mexican patients with multiple sclerosis.
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.
Neuromyelitis Optica Following Human Papillomavirus Vaccination.
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis.

Pages